<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150108</url>
  </required_header>
  <id_info>
    <org_study_id>SHP634-102</org_study_id>
    <nct_id>NCT03150108</nct_id>
  </id_info>
  <brief_title>Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneously in Japanese Healthy Subjects Compared With Matched Non-Hispanic, Caucasian Healthy Adult Subjects and to Assess Dose Proportionality of 3 Doses of rhPTH(1-84) in the Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare how rhPTH(1-84) affects the body between healthy
      adults of Japanese descent and matched, healthy Caucasian adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Actual">June 26, 2017</completion_date>
  <primary_completion_date type="Actual">June 26, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) of rhPTH(1-84) in Plasma</measure>
    <time_frame>NHC:30 and 90 minutes (mins) PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 hours (h) (Day 1), 24 h (Day 2) JD: 30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Days 1,4,7),24 h (Days 2,5,8)</time_frame>
    <description>Maximum concentration occurring at time of maximum observed concentration (total and baseline adjusted) of rhPTH(1-84) administered as a single subcutaneous (SC) dose of 100 microgram (mcg) in plasma during a dosing interval between healthy adult volunteer subjects of Japanese descent and matched, non-Hispanic, healthy, adult Caucasian subjects. Pharmacokinetic (PK) parameters will be calculated from original and baseline-adjusted plasma concentration-time data using noncompartmental methods and all calculations will be based on actual sampling times. Here NHC refers to Non-Hispanic Caucasians and JD refers to Japanese Descents. PRD refers to predose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Drug Concentration (Tmax) of rhPTH(1-84) in Plasma</measure>
    <time_frame>NHC:30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Day 1), 24 h (Day 2) JD: 30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Days 1,4,7),24 h (Days 2,5,8)</time_frame>
    <description>Time to reach maximum observed drug concentration of rhPTH(1-84) administered as a single SC dose of 100 mcg in plasma during a dosing interval between healthy adult volunteer subjects of Japanese descent and matched, non-Hispanic, healthy, adult Caucasian subjects. PK parameters will be calculated from original and baseline-adjusted plasma concentration-time data using noncompartmental methods and all calculations will be based on actual sampling times. Here NHC refers to Non-Hispanic Caucasians and JD refers to Japanese Descents. PRD refers to predose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of rhPTH(1-84) in Plasma</measure>
    <time_frame>NHC:30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Day 1), 24 h (Day 2) JD: 30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Days 1,4,7),24 h (Days 2,5,8)</time_frame>
    <description>Area under the curve from the time of dosing to the last measurable concentration (total and baseline-adjusted) of rhPTH(1-84) administered as a single SC dose of 100 mcg in plasma during a dosing interval between healthy adult volunteer subjects of Japanese descent and matched, non-Hispanic, healthy, adult Caucasian subjects. PK parameters will be calculated from original and baseline-adjusted plasma concentration-time data using noncompartmental methods and all calculations will be based on actual sampling times. Here NHC refers to Non-Hispanic Caucasians and JD refers to Japanese Descents. PRD refers to predose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First Order Rate Constant (Lambda z) Associated With the Terminal (Log-Linear) Portion of the Curve for rhPTH(1-84)</measure>
    <time_frame>NHC:30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Day 1), 24 h (Day 2) JD: 30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Days 1,4,7),24 h (Days 2,5,8)</time_frame>
    <description>Lambda z is first order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve. PK parameters will be calculated from original and baseline-adjusted plasma concentration-time data using noncompartmental methods and all calculations will be based on actual sampling times. Here NHC refers to Non-Hispanic Caucasians and JD refers to Japanese Descents. PRD refers to predose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t1/2) of rhPTH(1-84) in Plasma</measure>
    <time_frame>NHC:30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Day 1), 24 h (Day 2) JD: 30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Days 1,4,7),24 h (Days 2,5,8)</time_frame>
    <description>Terminal half-life is the time measured for the plasma concentration of rhPTH(1-84) administered as a single SC dose of 100 mcg during a dosing interval between healthy adult volunteer subjects of Japanese descent and matched, non-Hispanic, healthy, adult Caucasian subjects in plasma to decrease by one half. PK parameters will be calculated from original and baseline-adjusted plasma concentration-time data using noncompartmental methods and all calculations will be based on actual sampling times. Here NHC refers to Non-Hispanic Caucasians and JD refers to Japanese Descents. PRD refers to predose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/F) After Subcutaneous Administration of rhPTH(1-84)</measure>
    <time_frame>NHC:30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Day 1), 24 h (Day 2) JD: 30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Days 1,4,7),24 h (Days 2,5,8)</time_frame>
    <description>CL/F is defined as the volume of plasma cleared of the drug per unit time when administered as a single SC dose of 100 mcg in plasma during a dosing interval between healthy adult volunteer subjects of Japanese descent and matched, non-Hispanic, healthy, adult Caucasian subjects. PK parameters will be calculated from original and baseline-adjusted plasma concentration-time data using noncompartmental methods and all calculations will be based on actual sampling times. Here NHC refers to Non-Hispanic Caucasians and JD refers to Japanese Descents. PRD refers to predose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vdz/F) After Subcutaneous Administration of rhPTH(1-84)</measure>
    <time_frame>NHC:30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Day 1), 24 h (Day 2) JD: 30 and 90 mins PRD, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Days 1,4,7),24 h (Days 2,5,8)</time_frame>
    <description>Vdz/F is defined as the theoretical volume into which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vdz/F is influenced by the fraction absorbed. PK parameters will be calculated from original and baseline-adjusted plasma concentration-time data using noncompartmental methods and all calculations will be based on actual sampling times. Here NHC refers to Non-Hispanic Caucasians and JD refers to Japanese Descents. PRD refers to predose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Proportionality for Maximum Observed Drug Concentration (Cmax) of rhPTH(1-84)</measure>
    <time_frame>30 and 90 mins predose, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Days 1,4,7),24 h (Days 2,5,8)</time_frame>
    <description>Dose proportionality will be assessed for maximum concentration occurring at time of maximum observed concentration of rhPTH(1-84) during a dosing interval when exposed to single SC doses of rhPTH(1-84) at 25 mcg, 50 mcg and 100 mcg in healthy adult volunteer subjects of Japanese descent. Dose proportionality for Cmax will be assessed using the power model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Proportionality for Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of rhPTH(1-84)</measure>
    <time_frame>30 and 90 mins predose, 10,20,30,45 mins, 1,1.25,1.5,2,2.5,3,4,6,8,12,16 h (Days 1,4,7),24 h (Days 2,5,8)</time_frame>
    <description>Dose proportionality will be assessed for area under the curve from the time of dosing to the last measurable concentration of rhPTH(1-84) during a dosing interval when exposed to single SC doses of rhPTH(1-84) at 25 mcg, 50 mcg and 100 mcg in healthy adult volunteer subjects of Japanese descent. Dose proportionality for AUClast will be assessed using the power model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Profile Comparison in Serum Calcium and Phosphate Levels of rhPTH(1-84)</measure>
    <time_frame>Non-Hispanic Caucasians: 30 mins predose, 4, 8 and 12 h (Day 1),24 h (Day 2) Japanese Descents: 30 mins predose, 4, 8 and 12 h (Days 1, 4, 7), 24 h (Days 2, 5, 8)</time_frame>
    <description>PD profiles in serum calcium and phosphate will be compared in healthy adult volunteer subjects of Japanese descent and matched, non-Hispanic, healthy, adult Caucasian subjects when exposed to 100 mcg SC injection of rhPTH(1-84). Pharmacodynamic parameters will be computed from individual post dose values of serum calcium (uncorrected and corrected for serum albumin levels and both unadjusted and baseline adjusted) and phosphate using non-compartmental methods. PD parameters include AUClast, tmax, Emax and TEmax. PD parameters will be estimated based on both original and baseline-adjusted values of serum calcium and phosphate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD Profiles in Serum Calcium and Phosphate Levels of rhPTH(1-84)</measure>
    <time_frame>Non-Hispanic Caucasians: 30 mins predose, 4, 8 and 12 h (Day 1),24 h (Day 2) Japanese Descents: 30 mins predose, 4, 8 and 12 h (Days 1, 4, 7), 24 h (Days 2, 5, 8)</time_frame>
    <description>PD profiles in serum calcium and phosphate will be assessed in healthy adult volunteer subjects of Japanese descent when exposed to 25 mcg and 50 mcg SC injection of rhPTH(1-84). Pharmacodynamic parameters will be computed from individual post dose values of serum calcium (uncorrected and corrected for serum albumin levels and both unadjusted and baseline adjusted) and phosphate using non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of rhPTH(1-84) as measured by treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From start of study drug administration to follow-up (up to 40 days)</time_frame>
    <description>Safety and tolerability will be determined through assessment of treatment-emergent adverse events (TEAEs), vital signs, electrocardiogram (ECG) findings, and clinical laboratory evaluations for the non-Hispanic, Caucasian subjects and for the subjects of Japanese descent.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>Non-Hispanic Caucasians</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single dose of 100 microgram (mcg) rhPTH(1-84) subcutaneous (SC) injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Descents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhPTH(1-84)</intervention_name>
    <description>25 mcg rhPTH(1-84) SC injection</description>
    <arm_group_label>Japanese Descents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhPTH(1-84)</intervention_name>
    <description>50 mcg rhPTH(1-84) SC injection</description>
    <arm_group_label>Japanese Descents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhPTH(1-84)</intervention_name>
    <description>100 mcg rhPTH(1-84) SC injection</description>
    <arm_group_label>Non-Hispanic Caucasians</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to voluntarily provide written, signed, and dated informed consent as
             applicable to participate in the study.

          -  An understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

          -  Age 18-65 inclusive at the time of consent. The date of signature of the informed
             consent is defined as the beginning of the screening period. This inclusion criterion
             will only be assessed at the first screening visit.

          -  Subjects must be either:

               -  A subject of Japanese descent born in Japan, who has resided outside of Japan for
                  no longer than 5 years and is of Japanese parentage, defined as having 2 Japanese
                  parents, and 4 Japanese grandparents, all born in Japan.

               -  A non-hispanic, Caucasian subject who has 2 non-hispanic, Caucasian parents and 4
                  non-hispanic, Caucasian grandparents.

          -  Male or nonpregnant, nonlactating female who agrees to comply with any applicable
             contraceptive requirements of the protocol or females of nonchildbearing potential.

          -  Considered &quot;healthy&quot; by the investigator. Healthy status is defined by absence of
             evidence of any active or chronic disease following a detailed medical and surgical
             history, a complete physical examination including vital signs, 12-lead
             electrocardiogram (ECG), hematology, blood chemistry, and urinalysis.

          -  Body mass index between 18.5 and 28 kilogram per square meter (kg/m^2), inclusive,
             with a body weight greater than or equal to (&gt;=) 45 kg (99 pounds [lbs]). This
             inclusion criterion will only be assessed at the first screening visit.

          -  Willing and able to consume standardized meals during the confinement period of the
             study. All subjects will be required to consume the identical meals on study days when
             serial pharmacokinetic (PK) and pharmacodynamic (PD) blood samples are collected.

          -  A clinical safety laboratory parameter of hemoglobin greater than (&gt;) 11.7 gram per
             deciliter (g/dl) (females) or 13.1 g/dl (males) and less than (&lt;) 16 g/dl (females) or
             17.4 g/dl (males) or, if out of this range, deemed not clinically significant by the
             principal investigator.

          -  Total serum calcium within laboratory normal limits.

          -  Serum parathyroid hormone (PTH) levels within laboratory normal limits.

        Exclusion Criteria:

          -  History of any hematological, hepatic, respiratory, cardiovascular, renal,
             neurological or psychiatric disease, gall bladder removal, or current or recurrent
             disease that could affect the action, absorption, or disposition of the
             investigational product, or clinical or laboratory assessments.

          -  Current or relevant history of physical or psychiatric illness, any medical disorder
             that may require treatment or make the subject unlikely to fully complete the study,
             or any condition that presents undue risk from the investigational product or
             procedures.

          -  Known or suspected intolerance or hypersensitivity to the investigational product(s),
             closely-related compounds, or any of the stated ingredients.

          -  Significant illness, as judged by the investigator, within 2 weeks of the first dose
             of investigational product.

          -  Known history of alcohol or other substance abuse within the last year.

          -  Donation of blood or blood products (Example (eg), plasma or platelets) within 60 days
             prior to receiving the first dose of investigational product.

          -  Use of the following prior to administration of investigational product within:

               -  30 days - loop diuretics, lithium, antacids, systemic corticosteroids (medical
                  judgment is required by the investigator. Primarily high doses of systemic
                  corticosteroids [eg, prednisone] should be excluded. Stable doses of
                  hydrocortisone [eg, as treatment for Addison's disease] may be acceptable).

               -  3 months - calcitonin, cinacalcet hydrochloride, treatment with rhPTH(1-84) or
                  N-terminal PTH or PTH-related peptide fragments or analogs.

               -  For females: changes in hormone replacement therapy within 3 months are excluded.
                  Stable (≥3 months) hormone replacement therapy is acceptable.

               -  6 months - fluoride tablets, oral bisphosphonates, methotrexate, growth hormone,
                  digoxin, raloxifene or similar selective estrogen receptor modulators (SERMs).

               -  12 months - intravenous bisphosphonates, drug or alcohol abuse, as determined by
                  the investigator.

          -  Confirmed systolic blood pressure (BP) &gt;39 millimeter of mercury (mmHg) or &lt;89 mmHg,
             and diastolic BP &gt;89 mmHg or &lt;49 mmHg.

          -  Twelve-lead ECG demonstrating measure of time between the start of the Q wave and the
             end of the T wave using Fridericia's formula in an electrocardiogram (QTcF) &gt;450
             milliseconds (msec) at screening. If QTcF exceeds 450 msec, the ECG should be repeated
             2 more times and the average of the 3 QTcF values should be used to determine the
             subject's eligibility.

          -  Positive screen for drugs of abuse at screening or drugs of abuse or alcohol on Day
             -1.

          -  Male subjects who consume more than 21 units of alcohol per week or 3 units per day.
             Female subjects who consume more than 14 units of alcohol per week or 2 units per day.
             (1 alcohol unit=1 beer or 1 wine (5 ounce (oz) per 150 milliliter (mL)) or 1 liquor
             (1.5oz/40 mL) or 0.75 oz alcohol).

          -  Positive human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or
             hepatitis C virus (HCV) antibody screen.

          -  Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing
             products in any form (eg, gum, patch). Ex-users must report that they have stopped
             using tobacco for at least 30 days prior to receiving the first dose of
             investigational product.

          -  Routine consumption of more than 2 units of caffeine per day or subjects who
             experience caffeine withdrawal headaches. (1 caffeine unit is contained in the
             following items: one 6 oz (180 mL) cup of coffee, two 12 oz (360 mL) cans of cola, one
             12 oz cup of tea, three 1 oz (85 g) chocolate bars. Decaffeinated coffee, tea, or cola
             are not considered to contain caffeine).

          -  Prior screen failure, randomization, participation, or enrollment in this study or
             prior exposure to any exogenous PTH, PTH fragments or analogs.

          -  Current use of any medication (including over-the-counter, herbal, or homeopathic
             preparations; with the exception of hormonal replacement therapy or hormonal
             contraceptives and occasional use of ibuprofen and acetaminophen). Current use is
             defined as use within 14 days of the first dose of investigational product.

          -  History of abnormalities of calcium homeostasis including hyperparathyroidism,
             hypoparathyroidism, hyperthyroidism, osteoporosis, Cushing's syndrome, hypercalcemia,
             hypocalcemia, or any other calcium disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

